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ABSTRACT 
AIM: Breast cancer in New Zealand-based Pasifika women is a significant issue. Although Pasifika women 
have a lower incidence of breast cancer compared to New Zealand European women, they have higher 
breast cancer mortality and lower five-year survival. The aim of this study was to describe the characteristics 
and tumour biology of Pasifika women and to compare New Zealand European women to identify what 
factors impact on early (Stage 1 and 2) vs advanced stage (Stage 3 and 4) at diagnosis.
METHOD: Data on all Pasifika and New Zealand European women diagnosed with breast cancer (C50) 
during the period 1 June 2000 to 31 May 2013 was extracted from the Auckland and Waikato Breast Cancer 
Registries. Descriptive tables and Chi-square test were used to examine di erences in characteristics and 
tumour biology between Pasifika and New Zealand European women. Logistic regression was used to 
identify factors that contributed to an increased risk of advanced stage at diagnosis. 
RESULTS: A significantly higher proportion of Pasifika women had advanced disease at diagnosis compared 
to New Zealand European women (33.3% and 18.3%, respectively). Cancer biology in Pasifika women was 
more likely to be: 1) HER2+, 2) ER/PR negative and 3) have a tumour size of ≥50mm. Pasifika women live in 
higher deprivation areas of 9–10 compared to New Zealand European women (55% vs 14%, respectively) 
and were less likely to have their cancer identified through screening. Logistic regression showed that if 
Pasifika women were on the screen-detected pathway they had similar odds (not sig.) of having advanced 
disease at diagnosis to New Zealand European women. 
CONCLUSION: Mode of detection, deprivation, age and some biological factors contributed to the di erence 
in odds ratio between Pasifika and New Zealand European women. For those of screening age, adherence 
to the screening programme and improvements in access to earlier diagnosis for Pasifika women under the 
current screening age have the potential to make a substantial di erence in the number of Pasifika women 
presenting with late-stage disease.
Breast cancer is a signiﬁ cant health is-sue for women in New Zealand. There are approximately 3,000 registrations 
and around 600 deaths during 2012.1 One 
hundred and twenty Pasiﬁ ka women were 
registered during the calendar year 2012, 
with 31 deaths of Pasiﬁ ka women with 
breast cancer during the same period.1 Dif-
ferences for indigenous and ethnic minori-
ty populations around the world are well 
documented.2–5 Within New Zealand there 
are many examples of inequitable outcomes 
that disadvantage minority populations.6–13 
Māori and Pasiﬁ ka women with breast can-
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cer have been shown to have much poorer 
outcomes than their New Zealand European 
counterpart. This is often characterised by 
the frequency of late-stage disease at diag-
nosis.14–16
‘Pasiﬁ ka’ is a broad name for a heteroge-
neous group with a long history of migration 
to New Zealand from an array of island 
nations. Pasiﬁ ka people are currently the 
fourth largest ethnic group in New Zealand, 
accounting for 7.4% of the New Zealand 
population.17 The primary Pasiﬁ ka popu-
lation groups in New Zealand are Samoan, 
Cook Island, Tongan, Niuean, Fijian and 
Tokelauan. The average age of the Pasiﬁ ka 
population is younger than other groups 
at 21.1 years, compared to 41.0 years for 
New Zealand European. Approximately 
two-thirds of the current New Zealand 
Pasiﬁ ka population are New Zealand born.17 
Pasiﬁ ka women have been found to 
have a lower breast cancer incidence 
compared with other ethnic groups9,18 but 
have an increased risk of breast cancer-spe-
ciﬁ c mortality compared to New Zealand 
European women (Hazard ratio (HR) 1.25 
(Conﬁ dence Interval (CI) 0.94, 1.68)).12,19 
Pasiﬁ ka women are predominantly younger 
at diagnosis, come from more deprived 
areas and have larger tumour size with 
more ductal histology.19 Sarfati et al (2005) 
found that during the 1980s to end of 1990s 
Pasiﬁ ka women had a three-fold increase 
in breast-cancer mortality, from 11 to 96 
deaths during the period.12 Some of the 
major causes of disparity between the 
ethnic groups in New Zealand have been 
attributed to higher levels of deprivation 
and in particular, inadequate access to 
healthcare.20–22
The aim of this study was to describe 
the characteristics and tumour biology 
of Pasiﬁ ka women and compare to New 
Zealand European women registered on 
the Waikato and Auckland Breast Cancer 
Registers during 1 June 2000 and 31 May 
2013. The purpose was to consider which 
factors, including ethnicity, deprivation and 
mode of detection, impact on early (Stage 1 
and 2) vs advanced stage (Stage 3 and 4) at 
diagnosis and to determine differences in 
cancer biology between all women recorded 
as ‘Pasiﬁ ka’ and compare to New Zealand 
European women. Understanding the 
factors that contribute to poorer outcomes 
are important in addressing where to 
improve service provision. 
Methods
Data sources
Data on all Pasiﬁ ka and New Zealand 
European women diagnosed with breast 
cancer (C50) during the period 1 June 2000 
to 31 May 2013 was extracted from the 
Auckland and Waikato Breast Cancer Regis-
tries (referred to as the combined register). 
Both registries are computer-based data-
bases that conﬁ dentially capture all women 
diagnosed with breast cancer within their 
region. All women are placed on the register 
but can opt out if desired. The Waikato 
Breast Cancer Register began collecting data 
in November 2004, but undertook a back-
dating project to complete records back to 
1999. The Auckland Breast Cancer Register 
began in June 2000. Data collected and 
recorded on the register databases included: 
demographic details, mode of and char-
acteristics at presentation, comorbidities 
(also from the National Minimum Data Set 
(NMDS)), investigations and information on 
the management of the disease, follow-up 
and outcomes.
The combined register was linked to 
National Ministry of Health (MOH) datamart 
via patient National Health Index number 
(NHI). The NHI is a unique identiﬁ er 
assigned to all individuals that are New 
Zealand residents. National MOH datamart 
included the New Zealand Cancer Register 
(NZCR), NMDS (or hospital discharge data), 
Mortality Collection (MORT) and Death 
Certiﬁ cates. 
Study population
All Pasiﬁ ka and New Zealand European 
women with an invasive breast cancer regis-
tration in the Auckland and Waikato Regions 
during the period 1 June 2000 to 31 May 
2013 were included in the study. 
Study covariates
Ethnicity
Ethnicity was collated from all datasets 
using Statistics New Zealand Ethnicity 
Classiﬁ cation. This classiﬁ cation system is 
a hierarchical structure with four levels. 
For this study, ethnicity has been coded to 
level two.23 Pasiﬁ ka ethnicity was assigned 
to a patient if they had any of the level one 
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or two ethnicity codes of 30 to 37, on any 
dataset.23 Pasiﬁ ka ethnicity was assigned 
from the datasets as follows: the combined 
registers: 832 women, and the MOH data-
bases: 109 women. From the NZCR, it was 
identiﬁ ed 20 women on the combined 
register had dual Māori and Pasiﬁ ka ethnic-
ities assigned and were included in the 
analysis as Pasiﬁ ka. 
Deprivation
Deprivation is derived by domicile at diag-
nosis. The New Zealand Deprivation Index 
(Dep Index) is a measure of nine factors 
(transport access, beneﬁ t, employment, 
income, communication access, single 
parent family, education, living space and 
home ownership) collected in the national 
census.24 The Dep Index is a scale of 1 to 10, 
least deprived to most deprived. 
Stage
Cancer stage at diagnosis is classiﬁ ed from 
clinical notes within the respective breast 
cancer registers.  Tumours are categorised 
into four cancer stages based on the size of 
the tumour and the extent of spread. Stage 
1 is small and conﬁ ned within the organ. 
Stage 2 usually means the cancer has not 
spread onto surrounding tissue but may 
have spread to the lymph nodes close to the 
tumour. Stage 3 is a larger cancer with some 
spread to the surrounding tissue and lymph 
nodes. Stage 4 is the spread of the cancer to 
other organ/s. Advanced disease is deﬁ ned 
as Stage 3 and 4.25
Comorbidity—Cancer, Care and 
Comorbidity Index (C3)
Comorbidities were identiﬁ ed from the 
National Minimum Data Set (NMDS) or 
hospital discharge data—those that had a 
hospital stay. Comorbidities were scored 
using the C3 score, a validated alternative 
to the Charlson and NCI indices in cancer 
populations.26 The index collects up to 
50 conditions to achieve a score. C3 only 
considers conditions that require hospital 
admission and overnight stay. Each regis-
tered comorbidity is coded on to the NMDS, 
which is a collection of all patient presen-
tations (overnight) to hospital and if the 
comorbidity is recorded during the visit by a 
healthcare practitioner on the clinical note. 
Mode of detection
Mode of detection has been categorised 
into two groups: screen-detected and 
non-screen detected. 1) Screen-detected: 
in New Zealand Breast Screen Aotearoa 
(BSA), a publicly funded national screening 
programme that facilitates the access 
of women that ﬁ t eligibility criteria to 
attend and participate in the breast screen 
programme was introduced in December 
1998. The screening programme was origi-
nally targeting women in the 50- to 64-year 
age bracket. The age range was extended 
during 2004 to include the following 
criteria: aged between 45 and 69 years; no 
symptoms of breast cancer; no mammogram 
in the previous 12 months; not pregnant/
breastfeeding; New Zealand resident. 
Mammograms are available two-yearly 
for eligible women.27 Breast screening can 
still be undertaken in private facilities at 
patient expense. 2) Non-screen detected: 
are all those cancers not detected through 
screening and include those identiﬁ ed 
symptomatically. 
Statistical analyses
Statistical analysis was performed in 
SPSS (IBM Corporation, New York, NY, 
USA. Characteristics of women diag-
nosed with breast cancer are presented in 
descriptive tables. Chi-square testing for 
the difference between Pasiﬁ ka and New 
Zealand European women was under-
taken. Incidence-rates were calculated 
per 1,000 cases in two age categories: 
<45 years (pre-screening age) and 45–69 
years (screening age). Binary logistic 
regression was used to identify factors that 
contribute to the risk of being diagnosed 
with advanced stage disease (Stage 3 and 
4) compared to early stage breast cancer 
(Stage 1 and 2) in Pasiﬁ ka compared to New 
Zealand European women. Factors that 
were included were: ethnicity, age, year of 
diagnosis, mode of detection, deprivation, 
location (Auckland/Waikato), comorbidity 
score, oestrogen receptor status (ER), 
progestogen receptor status (PR) and human 
epidermal growth factor receptor 2 status 
(HER2). Stage of disease at diagnosis was 
examined as not-advanced (Stage 1 and 2) 
and advanced (Stage 3 and 4). 
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Ethical approval for the use of retro-
spective patient health data was granted for 
the study through the Northern A Health 
and Disability Ethics Committee, reference: 
12/NTA/42/AM01.
Results 
There were 14,456 breast cancers regis-
tered on the combined register. A total 
of 11,267 were identiﬁ ed as Pasiﬁ ka or 
New Zealand European, 941 and 10,326, 
respectively. Māori and other ethnic 
groups (n=3,189) were excluded. In-situ 
(Stage 0) cancers were excluded, leaving 
9,780 invasive primary breast cancers; 853 
Pasiﬁ ka women and 8,927 New Zealand 
European women (Table 1). Two-thirds of 
Pasiﬁ ka women were under 60 years old 
at the time of their diagnosis, compared to 
half of New Zealand European women. The 
average age for Pasiﬁ ka and New Zealand 
European women was 54 years and 60 years, 
respectively. Pasiﬁ ka women were more 
likely than New Zealand European women 
to be pre-menopausal at the time of their 
diagnosis (40.9% vs 26.7%, respectively). 
Table 1: Distribution of patient and tumour characteristics comparing Pasiﬁ ka and New Zealand Euro-
pean women registered in the Auckland and Waikato Breast Cancer Registers (2000–2013).
Pasifika women NZ European women
All stage Advanced All stage Advanced
n (%) n (% of all 
stage) 
n (%) n (% of all 
stage)
Odds 
ratio 
(OR)
P value
Age at diagnosis
<45 years 208 (24.4) 91 (43.8) 1,128 (12.60 314 (27.8) 2.02 <0.001
45–69 years 541 (63.4) 157 (29.0) 5,524 (61.9) 859 (15.6) 2.22 <0.001
70+ years 104 (12.2) 36 (34.6) 2,275 (25.5) 459 (20.2) 2.09 <0.001
Total 853 (100) 284 (33.3) 8,927 (100) 1,632 (18.3) 2.23 <0.001
Stage at diagnosis
Stage 1 240 (28.1) 4,000 (44.8)
Stage 2 329 (38.6) 3,291 (36.9)
Stage 3 196 (23) 1,283 (14.4)
Stage 4 88 (10.3) 349 (3.9)
Unknown 0 (0) 4 (0.04)
Menopausal status
Pre 349 (40.9) 139 (39.8) 2,383 (26.7) 541 (22.7) 2.25 <0.001
Peri 33 (3.9) 8 (24.2) 449 (5) 74 (16.5) 1.62 0.3653
Post 443 (51.9) 130 (29.3) 5,937 (66.5) 998 (16.8) 2.06 <0.001
Unknown 28 (3.3) 7 (25) 158 (1.8) 19 (12)
C3 score
0 631 (74.0) 212 (33.6) 6,969 (78.1) 1,248 (17.9) 2.32 <0.001
1 69 (8.1) 24 (34.8) 724 (8.1) 141 (19.5) 2.21 0.0045
2 61 (7.2) 18 (29.5) 511 (5.7) 100 (19.6) 1.72 0.0998
3 92 (10.8) 30 (32.6) 723 (8.1) 143 (19.8) 1.96 0.007
Year of diagnosis
2000–2003 168 (19.7) 56 (33.3) 2,249 (25.2) 386 (17.2) 2.41 <0.001
2004–2006 192 (22.5) 64 (33.3) 1,944 (21.8) 379 (19.5) 2.06 <0.001
2007–2009 220 (25.8) 76 (34.5) 2,132 (23.9) 423 (19.8) 2.13 <0.001
2010–2013 273 (32.0) 88 (32.2) 2,602 (29.1) 444 (17.1) 2.31 <0.001
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Region
Auckland 801 (93.9) 264 (33) 6,717 (75.2) 1,191 (17.7) 2.28 <0.001
Waikato 52 (6.1) 20 (38.5) 2,210 (24.8) 441 (20) 2.51 0.0019
Deprivation
1–2 42 (4.9) 14 (33.3) 2,183 (24.5) 372 (17) 2.43 0.0106
3–4 47 (5.5) 19 (40.4) 1,612 (18.1) 265 (16.4) 3.45 <0.001
5–6 99 (11.6) 25 (25.3) 2,027 (22.7) 357 (17.6) 1.58 0.0720
7–8 188 (22) 60 (31.9) 1,765 (19.8) 377 (21.4) 1.73 0.0013
9–10 466 (54.6) 160 (34.3) 1,264 (14.2) 251 (19.9) 2.11 <0.001
Missing 11 (1.3) 6 (54.5) 76 (0.9) 10 (13.2)
Mode of detection
Not screen detected 593 (69.5) 258 (43.5) 5,405 (60.5) 1,381 (25.6) 2.24 <0.001
Screen detected 260 (30.5) 26 (10) 3,522 (39.5) 251 (7.1) 1.45 0.1112
Grade
1 140 (16.4) 17 (12.1) 2,151 (24.1) 111 (5.2) 2.54 0.0010
2 361 (42.3) 110 (30.5) 3,937 (44.1) 678 (17.2) 2.11 <0.001
3 297 (34.8) 130 (43.8) 2,340 (26.2) 633 (27.1) 2.10 <0.001
Unknown 55 (6.4) 27 (49.1) 499 (5.6) 210 (42.1)
ER/PR status
ER and PR - 181 (21.2) 66 (36.5) 1,602 (17.9) 408 (25.5) 1.68 0.0020
ER and/or PR + 639 (74.9) 211 (33) 7,108 (79.6) 1,173 (16.5) 2.49 <0.001
Unknown 33 (3.9) 7 217 (2.4) 51
HER2 status
Positive 180 (21.1) 86 (47.8) 1,037 (11.6) 324 (31.2) 2.01 <0.001
Negative/Equivocal 477 (55.9) 150 (31.4) 5,738 (64.3) 996 (17.4) 2.18 <0.001
Not done 196 (23) 48 (24.5) 2,152 (24.1) 312 (14.5) 1.91 0.0003
Histology
Ductal 714 (83.7) 241 (33.8) 7,020 (78.6) 1,206 (17.2) 2.46 <0.001
Lobular 61 (7.2) 22 (36.1) 1,128 (12.6) 278 (24.6) 1.72 0.0645
Others incl. mixed 67 (7.9) 15 (22.4) 621 (7) 85 (13.7) 1.82 0.0823
Unknown 11 (1.3) 6 (54.5) 158 (1.8) 63 (39.9)
Tumour size
0–9 99 (11.6) 6 (6.1) 1393 (15.6) 37 (2.7) 2.36 0.0999
10–19 175 (20.5) 10 (5.7) 3,069 (34.4) 207 (6.7) 0.84 0.7075
20–29 157 (18.4) 26 (16.6) 2,007 (22.5) 285 (14.2) 1.20 0.4878
30–49 196 (23) 72 (36.7) 1,360 (15.2) 384 (28.2) 1.48 0.0183
50+ 152 (17.8) 120 (78.9) 600 (6.7) 437 (72.8) 1.40 0.1519
Unknown 74 (8.7) 50 (67.6) 498 (5.6) 282 (56.6)
Table 1: Distribution of patient and tumour characteristics comparing Pasiﬁ ka and New Zealand Euro-
pean women registered in the Auckland and Waikato Breast Cancer Registers (2000–2013) (continued).
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Over time, the number of breast cancers 
diagnosed increased over the period 2000 to 
2013, however the proportion of advanced 
cancers changed very little. Overall, breast 
cancers were more likely to be identiﬁ ed 
symptomatically, eg, palpable breast lump, 
nipple discharge. This was reﬂ ected in the 
stage at diagnosis with Pasiﬁ ka women 
2.6 times more likely to be diagnosed with 
Stage 4 breast cancers than New Zealand 
European women who are over one and a 
half times more likely than Pasiﬁ ka women 
to have Stage 1 disease at diagnosis. 
The characteristics of the breast cancer 
tumour differ between the two groups. 
Pasiﬁ ka women were less likely than New 
Zealand European women to be PR negative 
(30.6% and 34.1%, respectively) and more 
likely to be ER negative (23.4% and 18.4%, 
respectively). Pasiﬁ ka women were signiﬁ -
cantly more likely to be ER/PR negative (p 
value 0.002), be 1.8 times more likely to have 
a HER2 positive cancer (p value <0.0001) 
and have an increased likelihood of ductal 
cancer. The difference in size of tumour was 
substantial with Pasiﬁ ka women over 2.5 
times more likely to have a tumour 50mm or 
greater (p value <0.0001). Although nearly 
a quarter of women did not have a HER2 
status recorded in the register, the vast 
majority (70%) of missing HER2 status data 
was from 2000–2003 when HER2 status was 
not routinely tested for and recorded. The 
proportion of missing HER2 data was similar 
between Pasiﬁ ka and New Zealand European 
women (23.0% and 24.1%, respectively). 
Pasiﬁ ka women were signiﬁ cantly more 
likely to live in Auckland and be urban-
based. They were also signiﬁ cantly more 
likely to live in a higher deprivation area 
than New Zealand European women with 
54.6% of Pasiﬁ ka women in the highest 
deprived area (9–10) compared to 14.2% of 
New Zealand European women. Conversely, 
New Zealand European women with breast 
cancer were signiﬁ cantly more likely to live 
in the lowest deprivation areas compared 
to Pasiﬁ ka women (24.5% and 4.9%, 
respectively).
The C3 or comorbidity score was calcu-
lated from hospital discharge data, gathered 
from the National Minimum Data Set 
(NMDS). However, the majority of patients 
(78%) had no evidence of comorbidities. 
Pasiﬁ ka women tended to be more likely to 
have one or more comorbidities.
Across the period 2001–2012, a lower 
proportion of Pasiﬁ ka women were iden-
tiﬁ ed through screening compared to New 
Zealand European women (46.4% and 
55.4%, respectively). Figure 1 shows the 
screening rates of women aged 45–69 years 
old at diagnosis. Over time the trend has 
changed with the proportion of women diag-
nosed by screening increasing (Figure 1). 
Figure 1: Proportion of women aged 45 to 69 years diagnosed by screening annually (2001–2012).*
*Screening programme was initially 50 to 64 year olds during 2001–2004, then was extended to 45–69 year olds.
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Advanced stage of disease by 
ethnic group 
Nearly half of the Pasiﬁ ka women diag-
nosed with advanced stage at diagnosis 
were younger than 45 years old (43.8%), 
ie, younger than the screening age. This 
compares to less than one-third of New 
Zealand European women (27.8%). Within 
the older age categories 70 years plus, 
Pasiﬁ ka women were signiﬁ cantly less likely 
to be diagnosed than New Zealand European 
women (12.2% and 25.5%, respectively). 
Disparities in socio-economic factors and 
deprivation have been found to be asso-
ciated with poorer outcomes, including 
late stage of disease at diagnosis and worse 
mortality outcomes.28 Of those women with 
advanced stage disease at diagnosis, Pasiﬁ ka 
women were signiﬁ cantly more likely to 
live in high deprivation of 9–10 compared to 
New Zealand European women (34.3% and 
19.9%, respectively (OR 2.11; p <0.001)). 
The proportion of Pasiﬁ ka women 
diagnosed with advanced disease at diag-
nosis changed very little over time: from 
33.3% during 2000–2003 to 32.2% during 
2010–2013. The proportion of New Zealand 
European women with advanced disease at 
diagnosis remained below 20% during 2000–
2013. The mode of detection for advanced 
disease was primarily through non-screened 
methods. However, 10.0% and 7.1% of 
Pasiﬁ ka and New Zealand European women 
respectively with advanced stage breast 
cancer were diagnosed through screening. 
Factors associated with risk of 
Stage 3 and 4 diagnosis in Pasifika 
women compared to New Zealand 
European women
To understand the differences in outcomes 
for Pasiﬁ ka vs New Zealand European 
women we undertook separate age-strat-
iﬁ ed multivariate analyses to investigate the 
contribution of factors that were considered 
clinically or theoretically important to 
advanced stage disease at diagnosis (Tables 
2 and 3). For the screening age group 45–69 
years old, with an odds ratio (OR) of 2.22 
(1.819–2.710), we can account for 0.295 
of the contribution to increased odds for 
factors; demographic, disease, residential 
area, comorbidity and screening status. 
Both deprivation and the mode of detection 
(screening status) were the largest contrib-
uting signiﬁ cant factors within the model.
Table 2: Adjusted OR and 95% CI for factors associated with advanced stage breast cancer at diagnosis 
in 45–69 year old Pasiﬁ ka women compared to New Zealand European women.
Screening age 45–69 95% CI
OR Lower Upper P value
Unadjusted 2.220 1.819 2.710 <0.001
Adjusted for:
Demographics + Age 2.176 1.781 2.658 <0.001
+Year of diagnosis 2.185 1.788 2.670 <0.001
Disease factors + ER/PR status 2.277 1.857 2.793 <0.001
Area of residence + Auckland/Waikato 2.341 1.904 2.878 <0.001
+ Deprivation 2.109 1.676 2.655 <0.001
Comorbidity + C3 score 2.073 1.645 2.612 <0.001
Healthcare access + Screening status 1.925 1.513 2.449 <0.001
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Although nearly a quarter of the HER2 
status information was missing, it was 
modelled in a second (not included) model 
to ascertain the contribution that HER2 
made. The contribution of HER2 to the 
disease factors of women in the screening 
age reduced the model from 1.925 to 1.864 
(1.421–2.433; p<0.001). 
For women diagnosed with breast cancer 
when they were younger than the screening 
age, ie, under 45 years old, the biggest 
contributing factor was deprivation (not 
sig.). HER2 status did not contribute to 
decreasing the OR (1.543; CI 1.044–2.280; p 
0.029) for this younger group. For this age 
group it is likely that factors outside of those 
presented contribute to the increased OR.
Contribution of mode of detection
To further understand the contribution 
of mode of presentation to advanced stage 
at diagnosis, we used forward stepwise 
logistic regression to analyse factors that 
contributed to the OR by screened vs 
non-screened detection pathways (Table 
4). For those cases that were not-screened 
detected, we found that very few of the 
variables used in the modelling process 
(as outlined within the method section) 
accounted for the increased OR between the 
ethnic groups. HER2 status and age were 
the only two factors that were signiﬁ cant to 
outcomes for those women diagnosed on the 
symptomatic (non-screen detected) pathway. 
However, these decreased OR marginally, 
from 2.242 to 2.133. 
Table 3: Adjusted OR and 95% CI for factors associated with advanced stage breast cancer at diagnosis 
in Pasiﬁ ka women compared to New Zealand European women younger than the screening age.
Younger than screening age <45yrs 95% CI
OR Lower Upper P value
Unadjusted 2.016 1.489 2.731 <0.001
Adjusted for:
Demographics + Age 2.018 1.489 2.734 <0.001
+Year of diagnosis 1.999 1.469 2.720 <0.001
Disease factors + ER/PR status 1.973 1.445 2.694 <0.001
Area of residence + Auckland/Waikato 2.027 1.479 2.777 <0.001
+ Deprivation 1.546 1.078 2.216 0.018
Comorbidity + C3 score 1.543 1.076 2.211 0.018
Table 4: Adjusted OR and 95% CI derived from forward stepwise multivariate analyses for factors 
associated with advanced stage breast cancer at diagnosis in Pasiﬁ ka women compared to New Zealand 
European women by mode of presentation (not stratiﬁ ed by age).
95% CI
Not screen detected OR Lower Upper P value
A. Ethnicity 2.242 1.885 2.667 <0.001
B. Ethnicity + HER2 2.231 1.825 2.729 <0.001
C. Ethnicity + HER2 + Age 2.133 1.740 2.614 <0.001
Screen detected cases
A. Ethnicity 1.495 0.967 2.313 0.071
B. Ethnicity + HER2 1.390 0.859 2.249 0.180
C. Ethnicity + HER2 + ER/PR status 1.368 0.843 2.220 0.205
D. Ethnicity + HER2 + ER/PR status + deprivation 1.174 0.706 1.952 0.537
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In contrast, nearly all the difference in 
OR for women who were diagnosed on a 
screen detected pathway was accounted 
for. Despite not reaching signiﬁ cance, 
HER2 status, ER/PR status and deprivation 
accounted for much of the increased OR for 
advanced stage at diagnosis, highlighting 
that if we can ensure that Pasiﬁ ka women 
are on a screened pathway their risk of 
being diagnosed with advanced stage at 
presentation decreased substantially, with 
an adjusted OR of 1.174.
Discussion
Early stage breast cancer at diagnosis 
typically has a better prognosis than for 
those with more advanced disease. Pasiﬁ ka 
women within our study population were 
more likely to be younger at diagnosis, 
nearly twice as likely to be diagnosed at an 
advanced stage (Stage 3 and 4) and over 
two and a half times more likely to be diag-
nosed with metastatic disease than New 
Zealand European women. The higher odds 
of having advanced disease at diagnosis 
contributes negatively to outcomes from 
breast cancer for this population group.29 
Factors that contributed to increased risk 
were aligned to what other researchers 
have found, that deprivation and mode 
of detection have a signiﬁ cant impact on 
advanced stage disease at diagnosis.12–15 
Biological factors, HER2 status and ER/
PR status contributed in a small way to 
increased risk of being diagnosed with 
more advanced disease. Pasiﬁ ka women 
were more likely to have a tumour equal to 
or greater than 50mm at diagnosis, more 
than twice as likely than for a New Zealand 
European woman. For Pasiﬁ ka women 
who were post-menopausal this was 2.2 
times greater than New Zealand European 
women. Adjusting for factors such as comor-
bidities and biological status made little 
difference to the risk of advanced disease. 
The year 2005 was a signiﬁ cant year for 
Pasiﬁ ka women. This was the year that 
Pasiﬁ ka women had the lowest proportion 
of cancers diagnosed through screening 
(8.3%) and this was also the year that the 
screening age was extended to include 
women aged 45–49 years and 65–69 years.30 
The drop from over 40% detected by 
screening in 2004 to 8% in 2005 highlighted 
the signiﬁ cant disparity between the ethnic-
ities during that period. Since 2008, over 
50% of all breast cancers diagnosed were 
identiﬁ ed through screening. 
Regular two-yearly breast screening has 
been shown to reduce the population risk 
of dying from breast cancer by about 30%.31 
Breast Screen Aotearoa (BSA) has focused 
on improving the participation of Pasiﬁ ka 
women in mammography screening across 
New Zealand. This has resulted in partic-
ipation rates of 72% for Pasiﬁ ka women, 
exceeding the targeted coverage of 70% 
in the two years ending 31 March 2016.32 
Trends within BSA data highlight that 
participation of Pasiﬁ ka women has steadily 
increased, and this has been linked to the 
decreased mortality rate in ‘ever-screened’ 
Pasiﬁ ka women.30 
Despite increased participation rates of 
Pasiﬁ ka women in the national screening 
programme, we found that Pasiﬁ ka women 
were less likely than New Zealand European 
women to be diagnosed through screening 
and more likely to be diagnosed at an 
advanced stage. There was also very little 
stage-shift in advanced disease at diagnosis 
for Pasiﬁ ka women and no change to the 
gap between Pasiﬁ ka and New Zealand 
European women. This could be due to 
an array of factors, including the younger 
age of the Pasiﬁ ka population. However, 
the expected rate of reduction of advanced 
stage at diagnosis can differ from the actual 
proportion of late stage presentation for 
other reasons, including diagnostic improve-
ments resulting in stage migration.33 
Pasiﬁ ka women are inequitably repre-
sented in areas of high deprivation. This may 
have some impact on access to timely and 
high-quality healthcare, including delays in 
diagnosis and treatment timeliness. High 
deprivation may also contribute to decreased 
accessibility to other facilities, for example 
private care. TinTin et al (2016) identiﬁ ed 
that outcomes were better for those able to 
access healthcare from a private institution 
compared to the public system.34
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Conclusion
Mode of detection, deprivation, age 
and tumour biology contribute to the risk 
of having advanced disease for Pasiﬁ ka 
compared to New Zealand European women 
diagnosed with breast cancer. Proportion-
ately, more Pasiﬁ ka women are diagnosed 
with breast cancer younger than the 
screening age. Access to diagnostics from a 
younger age could facilitate diagnosis at an 
earlier stage for this group. 
Pasiﬁ ka women with breast cancer are 
much more likely to live with high depri-
vation. This disproportionately inhibits 
access to care. Addressing how women 
are diagnosed and improving access to 
earlier diagnosis has the potential to make 
a difference in numbers of Pasiﬁ ka women 
who present with late stage disease. If 
screened regularly, Pasiﬁ ka women have a 
similar proportion of advanced disease as 
New Zealand European women. 
Further investigation into barriers to early 
presentation and early access to diagnostics 
is necessary to identify improved routes to 
diagnosis for the younger Pasiﬁ ka popu-
lation, and those that are outside of the 
screening age, to improve outcomes for this 
group. 
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